Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE
- Publication Information:
Original Publication: [Amsterdam] : Elsevier B.V., [2018]-
- Subject Terms:
- Abstract:
Context: There is a lack of comprehensive data regarding the factors that influence the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) to detect and localize clinically significant prostate cancer (csPCa).
Objective: To systematically review the current literature assessing the factors influencing the variability of mpMRI performance in csPCa diagnosis.
Evidence Acquisition: A computerized bibliographic search of Medline/PubMed database was performed for all studies assessing magnetic field strength, use of an endorectal coil, assessment system used by radiologists and inter-reader variability, experience of radiologists and urologists, use of a contrast agent, and use of computer-aided diagnosis (CAD) tools in relation to mpMRI diagnostic accuracy.
Evidence Synthesis: A total of 77 articles were included. Both radiologists' reading experience and urologists'/radiologists' biopsy experience were the main factors that influenced diagnostic accuracy. Therefore, it is mandatory to indicate the experience of the interpreting radiologists and biopsy-performing urologists to support the reliability of the findings. The most recent Prostate Imaging Reporting and Data System (PI-RADS) guidelines are recommended for use as the main assessment system for csPCa, given the simplified and standardized approach as well as its particular added value for less experienced radiologists. Biparametric MRI had similar accuracy to mpMRI; however, biparametric MRI performed better with experienced readers. The limited data available suggest that the combination of CAD and radiologist readings may influence diagnostic accuracy positively.
Conclusions: Multiple factors affect the accuracy of mpMRI and MRI-targeted biopsy to detect and localize csPCa. The high heterogeneity across the studies underlines the need to define the experience of radiologists and urologists, implement quality control, and adhere to the most recent PI-RADS assessment guidelines. Further research is needed to clarify which factors impact the accuracy of the MRI pathway and how.
Patient Summary: We systematically reported the factors influencing the accuracy of multiparametric magnetic resonance imaging (mpMRI) in detecting clinically significant prostate cancer (csPCa). These factors are significantly related to each other, with the experience of the radiologists being the dominating factor. In order to deliver the benefits of mpMRI to diagnose csPCa, it is necessary to develop expertise for both radiologists and urologists, implement quality control, and adhere to the most recent Prostate Imaging Reporting and Data System assessment guidelines.
(Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- References:
J Magn Reson Imaging. 2019 Feb;49(2):546-555. (PMID: 30187600)
Eur Urol. 2013 Jan;63(1):125-40. (PMID: 22743165)
Anticancer Res. 2017 Mar;37(3):1263-1271. (PMID: 28314291)
Radiology. 2016 Sep;280(3):793-804. (PMID: 27035179)
Eur Urol Focus. 2020 Mar 15;6(2):267-272. (PMID: 30327280)
Urol Oncol. 2016 Jun;34(6):255.e7-255.e13. (PMID: 26971190)
Eur Radiol. 2019 Aug;29(8):4150-4159. (PMID: 30456585)
Eur Radiol. 2018 Oct;28(10):4407-4417. (PMID: 29651763)
BJU Int. 2019 Aug;124(2):209-220. (PMID: 30929292)
AJR Am J Roentgenol. 2017 Mar;208(3):W92-W100. (PMID: 28026201)
Eur Urol. 2019 Apr;75(4):570-578. (PMID: 30477981)
Sci Rep. 2017 Feb 01;7:40640. (PMID: 28145525)
Abdom Radiol (NY). 2016 Nov;41(11):2218-2226. (PMID: 27369051)
Australas Phys Eng Sci Med. 2019 Mar;42(1):3-25. (PMID: 30762223)
World J Urol. 2020 Apr;38(4):981-991. (PMID: 31175458)
Eur Urol. 2019 Nov;76(5):574-581. (PMID: 31167748)
Eur J Radiol. 2016 Jun;85(6):1125-31. (PMID: 27161062)
Eur J Radiol. 2017 May;90:192-197. (PMID: 28583633)
Acad Radiol. 2004 Aug;11(8):857-62. (PMID: 15354305)
Radiology. 2015 May;275(2):458-68. (PMID: 25599415)
Eur Radiol. 2010 Apr;20(4):995-1002. (PMID: 19921205)
J Magn Reson Imaging. 2017 Oct;46(4):1089-1095. (PMID: 28165653)
Eur Urol. 2016 Jan;69(1):41-9. (PMID: 26361169)
Eur J Radiol. 2019 Jul;116:180-185. (PMID: 31153562)
J Urol. 2019 Mar;201(3):496-502. (PMID: 30273608)
Curr Probl Diagn Radiol. 2019 Mar - Apr;48(2):132-141. (PMID: 29428182)
Prostate Cancer Prostatic Dis. 2019 Dec;22(4):546-551. (PMID: 30842585)
BJU Int. 2016 Jan;117(1):80-6. (PMID: 25099182)
J Magn Reson Imaging. 2014 Jun;39(6):1443-8. (PMID: 24243824)
Curr Urol. 2019 Mar 8;12(2):88-96. (PMID: 31114466)
Urology. 2013 Jan;81(1):12-5. (PMID: 23273070)
Eur Urol. 2020 Apr;77(4):457-468. (PMID: 31582290)
Eur Radiol. 2012 Apr;22(4):746-57. (PMID: 22322308)
AJR Am J Roentgenol. 2013 Oct;201(4):W612-8. (PMID: 24059400)
Acad Radiol. 2015 Apr;22(4):467-74. (PMID: 25579637)
Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046)
J Urol. 2018 Nov;200(5):1022-1029. (PMID: 29886090)
Eur Radiol. 2017 Jun;27(6):2259-2266. (PMID: 27778089)
Lancet Oncol. 2019 Jan;20(1):100-109. (PMID: 30470502)
Oncol Lett. 2018 Sep;16(3):3201-3206. (PMID: 30127915)
Acad Radiol. 2004 Aug;11(8):863-7. (PMID: 15288036)
Rofo. 2012 Oct;184(10):925-9. (PMID: 22744328)
AJR Am J Roentgenol. 2017 Dec;209(6):W365-W373. (PMID: 28981356)
Int Urol Nephrol. 2017 Sep;49(9):1537-1544. (PMID: 28646483)
Oncotarget. 2018 Sep 18;9(73):33804-33817. (PMID: 30333911)
AJR Am J Roentgenol. 2019 Mar 27;:1-8. (PMID: 30917023)
Eur Urol Oncol. 2019 Mar;2(2):135-140. (PMID: 31017088)
Radiology. 2018 Oct;289(1):128-137. (PMID: 30063191)
Med Phys. 2003 Sep;30(9):2390-8. (PMID: 14528961)
Eur Radiol. 2015 Nov;25(11):3187-99. (PMID: 26060063)
Prostate Cancer Prostatic Dis. 2017 Dec;20(4):436-441. (PMID: 28762373)
Eur Urol Focus. 2019 Jul;5(4):592-599. (PMID: 29226826)
Clin Radiol. 2017 Jan;72(1):23-32. (PMID: 27726850)
Clin Imaging. 2015 Jan-Feb;39(1):85-8. (PMID: 25457525)
Eur Radiol. 2019 Sep;29(9):4754-4764. (PMID: 31187216)
Radiology. 2013 Nov;269(2):482-92. (PMID: 23788719)
J Magn Reson Imaging. 2019 Jun;49(6):1694-1703. (PMID: 30575184)
Eur Radiol. 2017 Oct;27(10):4082-4090. (PMID: 28374077)
J Comput Assist Tomogr. 2006 May-Jun;30(3):355-61. (PMID: 16778606)
Eur Urol Oncol. 2018 Jun;1(2):120-128. (PMID: 31100235)
Int Urol Nephrol. 2018 Jan;50(1):13-19. (PMID: 29188489)
Ann R Coll Surg Engl. 2017 Mar;99(3):218-223. (PMID: 27659356)
World J Urol. 2019 Oct;37(10):2119-2127. (PMID: 30560300)
World J Urol. 2019 Apr;37(4):691-699. (PMID: 30078170)
Chin Med J (Engl). 2018 Jul 20;131(14):1666-1673. (PMID: 29998885)
AJR Am J Roentgenol. 2019 Apr;212(4):839-846. (PMID: 30779662)
J Urol. 2014 Sep;192(3):648-58. (PMID: 24769030)
Clin Imaging. 2015 Jul-Aug;39(4):636-41. (PMID: 25735448)
Comput Biol Med. 2015 May;60:8-31. (PMID: 25747341)
Radiology. 2017 Nov;285(2):493-505. (PMID: 28727544)
Syst Rev. 2015 Jan 01;4:1. (PMID: 25554246)
Eur J Radiol. 2016 Jun;85(6):1075-84. (PMID: 27161055)
Abdom Imaging. 2015 Jan;40(1):134-42. (PMID: 25034558)
Eur Urol. 2020 Jan;77(1):78-94. (PMID: 31326219)
Eur Urol Oncol. 2019 Nov;2(6):605-616. (PMID: 31204311)
Eur Urol. 2011 Apr;59(4):477-94. (PMID: 21195536)
JAMA Netw Open. 2018 Jun 1;1(2):e180219. (PMID: 30646066)
World J Urol. 2018 May;36(5):687-691. (PMID: 29508048)
Acad Radiol. 2019 Aug;26(8):1017-1022. (PMID: 30268722)
PLoS One. 2016 Sep 22;11(9):e0162879. (PMID: 27657729)
Eur J Radiol. 2018 Apr;101:17-23. (PMID: 29571792)
Urology. 2019 May;127:68-73. (PMID: 30807773)
Chin Med J (Engl). 2016 20th Oct;129(20):2451-2459. (PMID: 27748338)
AJR Am J Roentgenol. 2005 Nov;185(5):1214-20. (PMID: 16247137)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
Radiology. 2014 Jun;271(3):761-9. (PMID: 24592959)
Yonsei Med J. 2017 Sep;58(5):994-999. (PMID: 28792144)
Eur Radiol. 2017 Jul;27(7):2776-2783. (PMID: 27957637)
Acta Radiol Open. 2016 Aug 17;5(8):2058460116663046. (PMID: 27583170)
Eur Radiol. 2017 Oct;27(10):4200-4208. (PMID: 28386721)
Radiology. 2013 Feb;266(2):521-30. (PMID: 23204542)
AJR Am J Roentgenol. 2017 Sep;209(3):W145-W151. (PMID: 28657843)
AJR Am J Roentgenol. 2017 Aug;209(2):339-349. (PMID: 28570099)
World J Urol. 2017 May;35(5):687-693. (PMID: 27510762)
Nat Rev Urol. 2020 Jan;17(1):41-61. (PMID: 31316185)
Eur Radiol. 2013 Nov;23(11):3185-90. (PMID: 23756958)
Eur J Radiol. 2016 Dec;85(12):2269-2274. (PMID: 27842676)
AJR Am J Roentgenol. 2019 Aug;213(2):384-396. (PMID: 31039022)
Eur Urol. 2019 Sep;76(3):284-303. (PMID: 31130434)
J Urol. 2014 Jul;192(1):67-74. (PMID: 24518762)
Radiology. 1999 Sep;212(3):817-27. (PMID: 10478252)
Abdom Radiol (NY). 2019 May;44(5):1883-1893. (PMID: 30788558)
Clin Radiol. 1998 Sep;53(9):673-81. (PMID: 9766721)
Prostate Cancer Prostatic Dis. 2019 May;22(2):331-336. (PMID: 30413806)
BJU Int. 2019 Mar;123(3):411-420. (PMID: 30240059)
Eur Urol. 2016 Jan;69(1):16-40. (PMID: 26427566)
Invest Radiol. 2013 Feb;48(2):92-7. (PMID: 23249646)
Abdom Radiol (NY). 2019 Mar;44(3):1062-1069. (PMID: 30324501)
J Belg Soc Radiol. 2016 Nov 24;100(1):108. (PMID: 30038991)
- Grant Information:
Z01 BC010655 United States ImNIH Intramural NIH HHS
- Contributed Indexing:
Keywords: Diagnosis, Multiparametric magnetic resonance imaging; Magnetic resonance imaging; Prostate cancer; Targeted biopsy
- Publication Date:
Date Created: 20200321 Date Completed: 20201204 Latest Revision: 20220329
- Publication Date:
20240829
- Accession Number:
PMC8942295
- Accession Number:
10.1016/j.euo.2020.02.005
- Accession Number:
32192942
No Comments.